Ask AI
ProCE Banner Activity

HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options

Podcast Episodes

Listen to Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss the new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer.

Released: October 14, 2025

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients, Inc

ProCE Banner

Supporters

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Disclosure

Primary Author

Amit Mahipal, MD, MPH: consultant/advisor/speaker: Astellas, AstraZeneca, Incyte, Taiho.

Shubham Pant, MD: consultant/advisor: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGBio, Bristol Myers Squibb, Daiichi Sankyo, Immuneering, Ipsen, Janssen, Jazz, Merck, Nihon Medi-Physics, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds; researcher (paid to institution): Amal Therapeutics, Arcus, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, CG Pharmaceuticals, Elicio, Immuneering, ImmunoMET, Incyte, Janssen, Jazz, Novartis, Pfizer, Revolution Medicine; individual publicly traded stock/stock options: OncoMed, Telperian.